The latest clinical trials of lung cancer immunotherapies: a review of literature

  • سال انتشار: 1403
  • محل انتشار: دومین کنگره بین المللی کنسرژنومیکس
  • کد COI اختصاصی: ICGCS02_058
  • زبان مقاله: انگلیسی
  • تعداد مشاهده: 103
دانلود فایل این مقاله

نویسندگان

Kimia Kazemzadeh

Universal Scientific Education and Research Network (USERN), Tehran, Iran

چکیده

Lung cancer remains a leading cause of cancer-related mortality worldwide. While chemotherapy has been the mainstay treatment, the emergence of immune checkpoint inhibitors (ICIs) targeting programmed death ۱ (PD-۱) and programmed death-ligand ۱ (PD-L۱) has revolutionized the management of non-small cell lung cancer (NSCLC). This narrative review aims to provide an update on the latest findings from clinical trials evaluating immunotherapies, particularly focusing on PD-۱/PD-L۱ inhibitors in various lung cancer treatment settings. Methods: A comprehensive literature search was conducted to identify the most promising clinical trials assessing the efficacy of PD-۱/PD-L۱ inhibitors, including nivolumab, pembrolizumab, atezolizumab, durvalumab, and avelumab, in lung cancer. The trials were evaluated based on their study design, patient population, and treatment outcomes. Results: PD-۱/PD-L۱ inhibitors have demonstrated significant anti-tumor activity in NSCLC, with some agents receiving FDA approval for first-line, second-line, and adjuvant therapy settings. A comprehensive analysis of ۱۱ clinical trials revealed that higher levels of PD-L۱ expression correlate with better responses to these inhibitors in both first-line and second-line therapies. Pembrolizumab has emerged as a highly effective first-line treatment for advanced NSCLC, particularly in patients exhibiting high PD-L۱ expression. In a pivotal phase III trial, pembrolizumab monotherapy significantly outperformed chemotherapy, yielding a median overall survival (OS) of ۳۰ months for patients with PD-L۱ expression of ۵۰% or greater, compared to ۱۴.۲ months for those receiving chemotherapy. For patients with PD-L۱ expression of at least ۱%, the median OS was ۱۶.۷ months versus ۱۲.۱ months for chemotherapy. Atezolizumab, recognized as the first anti-PD-L۱ antibody approved for NSCLC, has demonstrated both efficacy and safety as a second-line treatment option for advanced squamous and adenocarcinoma histologies. In a phase III trial, atezolizumab provided a median OS of ۱۳.۸ months, significantly better than the ۹.۶ months observed with docetaxel in previously treated NSCLC patients. Furthermore, combination therapies involving PD-۱/PD-L۱ inhibitors and chemotherapy have demonstrated promising results in improving survival rates. A meta-analysis revealed that the concurrent use of chemotherapy with PD-۱/PD-L۱ inhibitors, including pembrolizumab and atezolizumab, exhibited enhanced efficacy compared to chemotherapy alone in the first-line treatment of non-small cell lung cancer (NSCLC). Conclusion: While chemotherapy remains the current standard of care for lung cancer, the approval of specific ICI therapies for select lung cancer subtypes highlights the potential of these agents in becoming a cornerstone of standard care. However, overcoming challenges associated with ICI therapy, such as patient selection, biomarker identification, and management of immune-related adverse events, is crucial for optimizing their clinical benefit.

کلیدواژه ها

lung cancer, immunotherapy, clinical trial, immune checkpoint inhibitors

مقالات مرتبط جدید

اطلاعات بیشتر در مورد COI

COI مخفف عبارت CIVILICA Object Identifier به معنی شناسه سیویلیکا برای اسناد است. COI کدی است که مطابق محل انتشار، به مقالات کنفرانسها و ژورنالهای داخل کشور به هنگام نمایه سازی بر روی پایگاه استنادی سیویلیکا اختصاص می یابد.

کد COI به مفهوم کد ملی اسناد نمایه شده در سیویلیکا است و کدی یکتا و ثابت است و به همین دلیل همواره قابلیت استناد و پیگیری دارد.